CCN A.I CyberSecurity Scoring
28/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Critical Care Nutrition in 2026.
No incidents recorded for Critical Care Nutrition in 2026.
No incidents recorded for Critical Care Nutrition in 2026.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
Latest updates, reports, and threat intel affecting the global network.
State Street (NYSE:STT) has been appointed service provider for Dimensional Fund Advisors' first U.S. ETF share class structure.
From AI expansion to cyberwarfare, cybersecurity ETFs may offer a compelling investment opportunity.
Cloudflare and Mastercard announced a partnership to build cybersecurity tools for small businesses and critical infrastructure providers.
Jan 14 (Reuters) - Chinese authorities have told domestic companies to stop using cybersecurity software made by roughly a dozen firms from...
IntroductionIn response to population aging, the Chinese government has prioritized enhancing the age-friendly adaptation of digital technologies,...
Elevance Health's AI strategy fuses data, platforms, governance, trust to dominate personalized, proactive healthcare and insurance...
University of Guelph researchers have been awarded over $25.4 million from the Natural Sciences and Engineering Research Council (NSERC),...
The rapid integration of technology into healthcare systems has brought significant improvements in patient care and operational efficiency,...
CrowdStrike's chief technology officer. Those adversaries—espionage attacks that have increased from nations like China and Iran, as well as new...
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.22 and 4.0.0-RC1 through 4.17.15, an attacker with only a GitHub account can plant a JavaScript payload in a craftcms/cms issue title. When a Craft admin uses the CraftSupport widget’s "Give feedback" screen and types a search term that returns the poisoned issue, the payload executes in the admin’s control panel session. No control panel account or elevated privileges are required on the attacker’s side. This issue has been fixed in versions 4.17.16 and 5.9.23.
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.21 and 4.0.0-RC1 through 4.17.14, theAssetsController::actionDeleteFolder() only requires the deleteAssets:<volume-uid> permission for the target folder. It never enforces deletePeerAssets:<volume-uid>, even though Assets::deleteFoldersByIds() cascades deletion to every descendant folder and every asset inside, regardless of the uploader's assigned privileges. A low-privilege user who has been granted folder-management rights on a shared volume can therefore destroy assets uploaded by other users (peer assets), bypassing the per-asset peer-permission check that the sibling actionDeleteAsset endpoint correctly applies. This issue has been fixed in versions 4.17.15 and 5.9.22.
Craft CMS is a content management system (CMS). Versions 5.0.0-RC1 through 5.9.20, and 4.0.0-RC1 through 4.17.13 contain an authorization issue in the AssetsController::actionReplaceFile that can delete a source asset without source delete permission by supplying both assetId and sourceAssetId. AssetsController::actionReplaceFile() supports replacing a target asset file using another existing asset as the source. The action loads: assetId -> $assetToReplace and sourceAssetId -> $sourceAsset, then enforces replace permissions using ($assetToReplace ?: $sourceAsset). When both IDs are provided, this expression resolves to the target asset so no permission check is performed against the source asset volume. When both assets are present, Craft copies the source file into the target and then deletes the source asset. There is no deletion check for for the source asset. An authenticated user who can replace files in one volume can delete assets in another volume where they do not have delete permission, as long as they can obtain a sourceAssetId, leading to broken content references and data loss. This issue has been fixed in versions 4.17.14 and 5.9.21.
Description: To issue and renew TLS certificates on behalf of customers, Cloudflare's Universal SSL feature automatically manages the CAA RRset for the customer's zone. This auto-managed RRset is permissive by design (e.g. 'issue "letsencrypt.org"' without parameters). On Universal SSL zones, Cloudflare's authoritative DNS serves this auto-managed RRset at query time, superseding any customer-configured CAA records on the zone. When a customer publishes a stricter CAA record using the RFC 8657 accounturi or validationmethods parameters, the Certificate Authority does not observe those parameters when evaluating the served RRset under RFC 8659. As a result, the RFC 8657 account-binding and validation-method-binding protections are not enforced end-to-end on Universal SSL zones. Successful exploitation could result in issuance of a browser-trusted TLS certificate to an attacker, enabling MITM against the affected domain. Exploitation is non-trivial in practice: an attacker would need to hold an ACME account at one of the Certificate Authorities in the served CAA RRset and to simultaneously satisfy domain control validation across the multiple geographically distinct Network Perspectives the CA relies on for Multi-Perspective Issuance Corroboration. Cloudflare prefixes are anycast-announced from hundreds of locations globally, raising the bar against single-vantage-point BGP hijacks. Any resulting misissuance of a browser-trusted certificate is subject to Certificate Transparency logging required by major browsers, and would be visible to CT monitoring. Mitigation: Customers requiring strict RFC 8657 enforcement need to disable Universal SSL on the affected zone. Universal SSL's automatic CAA management and customer-set RFC 8657 accounturi and validationmethods enforcement are mutually exclusive by the nature of the issue, so there is no in-product workaround that preserves both. Certificate Transparency monitoring is recommended for all customers as a general detection control. Credits: David Osipov (ORCID: https://orcid.org/0009-0005-2713-9242), independent researcher
Out of bounds read and write in Tint in Google Chrome prior to 150.0.7871.46 allowed a remote attacker to potentially perform out of bounds memory access via a crafted HTML page. (Chromium security severity: High)
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.